Why the study?
Increasing refractory end-stage CHF and donor organ shortages in pediatric practice have made long-term mechanical circulatory support pressing, while prolonged anticoagulation carries risks of acute hemorrhagic stroke and bleeding.
Prolonged use of anticoagulant and antiplatelet therapy in pediatric patients on mechanical circulatory support carries a risk of life-threatening bleeding complications.
Answers are grounded in this paper and cite their sources.
May inform pediatric MCS strategies in refractory CHF; leaves open need for prospective outcome data.
Chronic heart failure (CHF) against the background of congenital heart disease, mostly in early childhood, or various forms of cardiomyopathies, more common in teenage age, represents an important cause of morbidity and mortality in the pediatric population [1, 2]. Due to the increase in the number of patients suffering from refractory end-stage CHF over the last two decades, and the current shortage of donor organs in pediatric practice, the issue of long-term mechanical circulatory support (MCS) is becoming increasingly a pressing problem. Patient management is a multidisciplinary task, since prolonged use of anticoagulant and antiplatelet therapy to prevent ventricular thrombosis has potentially life-threatening complications - acute hemorrhagic stroke and bleeding of varying severity.
No takes yet. Share an insight, caveat, or question.
Колоскова et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: